ijms-logo

Journal Browser

Journal Browser

Novel Insights into Molecular Biology of Urological Cancers 2.0

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Oncology".

Deadline for manuscript submissions: closed (31 December 2022) | Viewed by 5672

Special Issue Editor


E-Mail Website
Guest Editor

Special Issue Information

Dear Colleagues,

Kidney, prostate, and bladder cancers are among the most prevalent tumor types in male cancer cases, according to new estimates from the American Cancer Society.

In recent years, many studies have provided novel insights into the molecular mechanisms involved in urological tumor pathogenesis, leading to the identification of potential biomarkers for early diagnosis, risk assessment, and outcome prediction. Moreover, the introduction of high-throughput technologies has led to a greater understanding of the pathways underlying the development and progression of these tumors and the identification of novel potential therapeutic targets. This Special Issue of the International Journal of Molecular Sciences is dedicated to the application of different omics approaches to understand the perturbations of biological systems occurring in the pathogenesis of the genitourinary system.

Prof. Dr. Giuseppe Lucarelli
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • renal cell carcinoma
  • prostate cancer
  • bladder carcinoma
  • testicular tumors
  • omics
  • pathology

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review

26 pages, 7514 KiB  
Article
MUC1 Tissue Expression and Its Soluble Form CA15-3 Identify a Clear Cell Renal Cell Carcinoma with Distinct Metabolic Profile and Poor Clinical Outcome
by Giuseppe Lucarelli, Monica Rutigliano, Davide Loizzo, Nicola Antonio di Meo, Francesco Lasorsa, Mauro Mastropasqua, Eugenio Maiorano, Cinzia Bizzoca, Leonardo Vincenti, Michele Battaglia and Pasquale Ditonno
Int. J. Mol. Sci. 2022, 23(22), 13968; https://doi.org/10.3390/ijms232213968 - 12 Nov 2022
Cited by 45 | Viewed by 2128
Abstract
An altered metabolism is involved in the development of clear cell renal carcinoma (ccRCC). MUC1 overexpression has been found to be associated with advanced disease and poor prognosis. In this study, we evaluated the metabolomic profile of human ccRCC, according to MUC1 expression, [...] Read more.
An altered metabolism is involved in the development of clear cell renal carcinoma (ccRCC). MUC1 overexpression has been found to be associated with advanced disease and poor prognosis. In this study, we evaluated the metabolomic profile of human ccRCC, according to MUC1 expression, and integrated it with transcriptomic data. Moreover, we analyzed the role of MUC1 in sustaining ccRCC aggressiveness and the prognostic value of its soluble form CA15-3. Integrated metabolomic and transcriptomic analysis showed that MUC1-expressing ccRCC was characterized by metabolic reprogramming involving the glucose and lipid metabolism pathway. In addition, primary renal cancer cells treated with a small interfering RNA targeting MUC1 (siMUC1) migrated and proliferated at a slower rate than untreated cancer cells. After cisplatin treatment, the death rate of cancer cells treated with siMUC1 was significantly greater than that of untreated cells. Kaplan–Meier curves showed significant differences in CSS and PFS among groups of patients with high versus low levels of CA15-3. In a multivariate analysis, CA15-3 was an independent adverse prognostic factor for cancer-specific and progression-free survival. In conclusion, MUC1 expressing ccRCC is characterized by a particular metabolic reprogramming. The inhibition of MUC1 expression decreases cell motility and viability and improves cisplatin susceptibility, suggesting that this pathway can regulate de novo chemotherapy resistance in ccRCC. Full article
(This article belongs to the Special Issue Novel Insights into Molecular Biology of Urological Cancers 2.0)
Show Figures

Figure 1

Review

Jump to: Research

16 pages, 1249 KiB  
Review
Emerging Hallmarks of Metabolic Reprogramming in Prostate Cancer
by Francesco Lasorsa, Nicola Antonio di Meo, Monica Rutigliano, Matteo Ferro, Daniela Terracciano, Octavian Sabin Tataru, Michele Battaglia, Pasquale Ditonno and Giuseppe Lucarelli
Int. J. Mol. Sci. 2023, 24(2), 910; https://doi.org/10.3390/ijms24020910 - 4 Jan 2023
Cited by 19 | Viewed by 3127
Abstract
Prostate cancer (PCa) is the most common male malignancy and the fifth leading cause of cancer death in men worldwide. Prostate cancer cells are characterized by a hybrid glycolytic/oxidative phosphorylation phenotype determined by androgen receptor signaling. An increased lipogenesis and cholesterogenesis have been [...] Read more.
Prostate cancer (PCa) is the most common male malignancy and the fifth leading cause of cancer death in men worldwide. Prostate cancer cells are characterized by a hybrid glycolytic/oxidative phosphorylation phenotype determined by androgen receptor signaling. An increased lipogenesis and cholesterogenesis have been described in PCa cells. Many studies have shown that enzymes involved in these pathways are overexpressed in PCa. Glutamine becomes an essential amino acid for PCa cells, and its metabolism is thought to become an attractive therapeutic target. A crosstalk between cancer and stromal cells occurs in the tumor microenvironment because of the release of different cytokines and growth factors and due to changes in the extracellular matrix. A deeper insight into the metabolic changes may be obtained by a multi-omic approach integrating genomics, transcriptomics, metabolomics, lipidomics, and radiomics data. Full article
(This article belongs to the Special Issue Novel Insights into Molecular Biology of Urological Cancers 2.0)
Show Figures

Figure 1

Back to TopTop